Behind Noxopharm’s Announcement About the Chemotherapy Study

Posted on October 27th, 2016 by Blog Author

The details about the Phase 1 study announced yesterday are available at: Our main objective in this study is to see if NOX66 can make tumours respond to chemotherapy once they have become fully drug-resistant, and to do so using low dosages of chemotherapy. That’s an ambitious and novel objective, but one that in […]

Read More

October 2-month update by Dr Graham Kelly

Posted on October 7th, 2016 by Blog Author

It’s been 2 months since the listing and IPO. The first few months in the life of a drug development company is all about laying foundations. Everyone is looking for news flow as evidence of activity, but that requires first building the platforms that will deliver the news flow.  As the platforms are progressively built, […]

Read More